FTC Sets “New Normal” For Study Data Reviews, Prioritizes Health Product Claims Enforcement
This article was originally published in The Tan Sheet
Executive Summary
At the National Advertising Division Annual Conference, FTC Chairwoman Edith Ramirez said health claims and inadequate disclosures top the agency’s priorities following settlements with advertisers in 2013 and the recent Operation Full Disclosure initiative.
You may also be interested in...
FTC: All Advertisers Should Heed Lessons From “Operation Full Disclosure”
On the heels of FTC’s “Operation Full Disclosure,” which resulted in 60 warning letters, commission officials advise all advertisers to pay close attention to their disclosures and ensure they are clear and conspicuous. The initiative included review of 1,000 national television and print ads, and the agency says it will continue to monitor the advertising landscape for inadequate disclosure use.
In Brief: Abbott Outlook; CFSAN’s Landa To Retire; FTC Claim Substantiation
Abbott “on track” in China recovery; CFSAN seeks new director; FTC adds new substantiation elements to settlement; NAD advises iSatori to amend claims energy supplement claims; FDA wants proof deficiencies are corrected; and FDA warns about chelation supplement.
FTC Settles Big With Sensa, Other Weight-Loss Marketers
FTC settles with Sensa products and three other weight-loss product marketers, and launches its “gut check” voluntary media partnership program to prevent bogus claims. A firm cited in FTC’s 2011 investigation of human chorionic gonadotropin product ads also reached a settlement with the agency.